Financial Performance - For the three months ended September 30, 2022, the company reported revenue of RMB 103,223,000, an increase of 18.5% compared to RMB 87,072,000 for the same period in 2021[12]. - The gross profit for the third quarter of 2022 was RMB 45,757,000, representing a gross margin of approximately 44.3%[12]. - The net profit for the three months ended September 30, 2022, was RMB 12,645,000, compared to RMB 6,662,000 for the same period in 2021, indicating an increase of 90.0%[12]. - The earnings per share attributable to the parent company for the third quarter of 2022 was RMB 0.07, up from RMB 0.04 in the same quarter of 2021[12]. - For the nine months ended September 30, 2022, the company achieved total revenue of RMB 275,659,000, a growth of 5.3% from RMB 261,737,000 in the same period of 2021[12]. - The company reported a net profit of RMB 17,377,000 for the nine months ended September 30, 2022, compared to RMB 11,829,000 for the same period in 2021, reflecting an increase of 47.2%[12]. - The total comprehensive income for the three months ended September 30, 2022, was RMB 12,645,000, compared to RMB 6,638,000 for the same period in 2021[15]. Research and Development - Research and development expenses for the third quarter of 2022 were RMB 11,220,000, compared to RMB 9,962,000 in the same quarter of 2021, indicating a rise of 12.6%[12]. - The company aims to enhance product quality and develop new testing projects in line with industry technological advancements[37]. - The company's R&D investment for the first three quarters was over RMB 18.66 million, resulting in four patent grants during the reporting period[38]. Market Presence and Strategy - The company continues to focus on the research, development, production, and distribution of in vitro diagnostic reagent products, which remains its core business[19]. - The company aims to enhance its market presence and expand its product offerings in the in vitro diagnostics sector[19]. - The company reported a slight increase in revenue and profit compared to the same period last year due to participation in domestic pandemic prevention-related business[37]. - The company has achieved approximately 70% domestic substitution in biochemical diagnostic reagents, with the market size expected to reach RMB 11 billion[35]. - The company plans to optimize supplier relationships and direct procurement to continuously reduce raw material and overall costs[36]. Shareholder Information - The company's basic earnings per share for the nine months ended September 30, 2022, was calculated based on a weighted average of 144,707,176 shares, with no adjustments for potential diluted shares[27]. - As of September 30, 2022, Mr. Wu Lebin holds 3,500,878 shares, representing 4.35% of the company's domestic shares and 2.42% of the total registered capital[41]. - Beijing Puxai Asset Management Co., Ltd. directly holds 31,308,576 shares, accounting for 38.93% of the domestic shares and 21.64% of the total registered capital[44]. - Yunnan Shengneng Investment Partnership holds 10,939,314 domestic shares and 6,780,000 H shares, representing 13.60% and 10.55% of the respective categories[44]. Corporate Governance - The board of directors recommended not to distribute an interim dividend for the nine months ended September 30, 2022[30]. - The company's total reserves as of September 30, 2022, amounted to RMB 210,451,000, reflecting an increase from RMB 185,158,000 as of September 30, 2021[29]. - The Audit Committee, consisting of three independent non-executive directors, has reviewed the unaudited condensed consolidated financial statements for the period[58]. - The company has complied with all provisions of the GEM Listing Rules Appendix 15 Corporate Governance Code as of September 30, 2022, except for the provision D.2.5[59]. - The company has decided not to establish an internal audit department due to its scale and simple operational structure, but has implemented measures to fulfill internal audit functions[60]. - The board has engaged external consultants to conduct internal reviews as determined by the audit committee[60]. - The company believes that its existing organizational structure and close supervision by management ensure adequate risk management and internal control[60]. - The board will periodically review the necessity of establishing an internal audit function and may establish an internal audit team if needed[60]. Securities Transactions - The company has not purchased, sold, or redeemed any of its listed securities during the nine months ending September 30, 2022[54].
中生北控生物科技(08247) - 2022 Q3 - 季度财报